International Biotechnology Trust offers investors access to the fast growing biotechnology sector through an actively managed fund.
Business Model:
Revenue: $0
Employees: 0-0
Address: 71 Kingsway
City: London
State: england
Zip: WC2B 6ST
Country: GB
International Biotechnology Trust offers investors access to the fast growing biotechnology sector through an actively managed, diversified fund. Its award winning fund managers at SV Health Investors are scientifically and medically trained with over 60 years of experience in this specialist sector between them. As well as investing in a wide ranging portfolio of global quoted biotechnology stocks, they include a small proportion of otherwise inaccessible carefully selected unquoted investments which have the potential to deliver additional returns over the long term. Excellent management teams, unique innovative products and strong potential for outperformance are the key criteria for inclusion in their diversified portfolio of assets. International Biotechnology Trust offers investors the rare combination of high capital growth and sustainable dividend income. The Lead Investment Manager, Carl Harald Janson is celebrating his five year tenure with strong performance versus the benchmark, significantly outperforming the NBI on both a NAV and share price basis, with outperformances of 10.9% and 43.4% respectively. The NAV has also substantially outperformed the FTSE All-Share Index over the same period, with a return of 142.0% vs the index return of 44.1%.
Contact Phone:
Contact Email:
Listed Exchange:
LSE
IPO Date:
1/15/1999
Ticker Symbol:
IBT
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2007 | Sutro Biopharma | Venture Round | 0 |
5/2005 | Oxagen | Series B | 0 |
5/2000 | eBioinformatics | Venture Round | 0 |
10/2001 | Aderis Pharmaceuticals | Series D | 0 |
9/2012 | Karus Therapeutics | Series B | 7.6M |
11/2009 | Oxagen | Series C | 0 |
10/2005 | GlycoFi Inc. | Series C | 11M |
9/2012 | Karus Therapeutics | Series B | 0 |
11/2009 | Oxagen | Series C | 0 |
10/2007 | Sutro Biopharma | Venture Round | 0 |
10/2005 | GlycoFi Inc. | Series C | 0 |
5/2005 | Oxagen | Series B | 0 |
10/2001 | Aderis Pharmaceuticals | Series D | 0 |
5/2000 | eBioinformatics | Venture Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|